427 related articles for article (PubMed ID: 21110764)
1. Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies.
Saad F; Colombel M
Expert Rev Anticancer Ther; 2010 Dec; 10(12):1991-2002. PubMed ID: 21110764
[TBL] [Abstract][Full Text] [Related]
2. Optimal management of metastatic bone disease.
Major P
Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
[TBL] [Abstract][Full Text] [Related]
3. Preservation of bone health in prostate cancer.
Lattouf JB; Saad F
Curr Opin Support Palliat Care; 2007 Oct; 1(3):192-7. PubMed ID: 18685362
[TBL] [Abstract][Full Text] [Related]
4. Bone targeted therapies in metastatic castration-resistant prostate cancer.
Rajpar S; Fizazi K
Cancer J; 2013; 19(1):66-70. PubMed ID: 23337759
[TBL] [Abstract][Full Text] [Related]
5. Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.
Saad F; McKiernan J; Eastham J
Urol Oncol; 2006; 24(1):4-12. PubMed ID: 16414486
[TBL] [Abstract][Full Text] [Related]
6. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
Higano CS
Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
[TBL] [Abstract][Full Text] [Related]
7. Maintaining bone health in prostate cancer throughout the disease continuum.
Saad F; Eastham J
Semin Oncol; 2010 Jun; 37 Suppl 1():S30-7. PubMed ID: 20682370
[TBL] [Abstract][Full Text] [Related]
8. Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone.
Pouessel D; Culine S
Anticancer Drugs; 2012 Jan; 23(1):141-2. PubMed ID: 21934600
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates for treatment and prevention of bone metastases.
Michaelson MD; Smith MR
J Clin Oncol; 2005 Nov; 23(32):8219-24. PubMed ID: 16278476
[TBL] [Abstract][Full Text] [Related]
10. New results from the use of bisphosphonates in cancer patients.
Coleman R; Gnant M
Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
[TBL] [Abstract][Full Text] [Related]
11. New research findings on zoledronic acid: survival, pain, and anti-tumour effects.
Saad F
Cancer Treat Rev; 2008 Apr; 34(2):183-92. PubMed ID: 18061356
[TBL] [Abstract][Full Text] [Related]
12. Preserving bone health in patients with hormone-sensitive prostate cancer: the role of bisphosphonates.
Saad F; Abrahamsson PA; Miller K
BJU Int; 2009 Dec; 104(11):1573-9. PubMed ID: 20053188
[TBL] [Abstract][Full Text] [Related]
13. Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy.
Saad F; Sternberg CN
Nat Clin Pract Urol; 2007 Feb; 4 Suppl 1():S3-13. PubMed ID: 17264863
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Doggrell SA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
[TBL] [Abstract][Full Text] [Related]
15. The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel.
Saad F; Higano CS; Sartor O; Colombel M; Murray R; Mason MD; Tubaro A; Schulman C
Clin Genitourin Cancer; 2006 Mar; 4(4):257-62. PubMed ID: 16729908
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer and bone metastases: medical treatment.
Clark PE; Torti FM
Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S148-57. PubMed ID: 14600605
[TBL] [Abstract][Full Text] [Related]
18. Potential anticancer properties of bisphosphonates.
Neville-Webbe HL; Gnant M; Coleman RE
Semin Oncol; 2010 Jun; 37 Suppl 1():S53-65. PubMed ID: 20682373
[TBL] [Abstract][Full Text] [Related]
19. Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors.
Tchekmedyian NS; Chen YM; Saad F
Cancer Invest; 2010 Oct; 28(8):849-55. PubMed ID: 20590447
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer.
Saad F; Eastham J
Urology; 2010 Nov; 76(5):1175-81. PubMed ID: 21056263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
